ACM
IMNM icon

Atika Capital Management’s Immunome IMNM Stock Holding History

Atika Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.75M Sell
262,900
-71,441
-21% -$1.59M 0.72% 38
2025
Q4 		$7.18M Buy
+334,341
New +$5.87M 0.76% 43
2024
Q3 		– Sell
-74,000
Closed -$895K – 101
2024
Q2 		$895K Sell
74,000
-241,000
-77% -$3.77M 0.09% 89
2024
Q1 		$7.77M Buy
+315,000
New +$6.39M 0.77% 50

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Atika Capital Management's IMNM Position: Q1 2026 in Review

Atika Capital Management reduced its Immunome (IMNM) stake by 21% in Q1 2026, selling an estimated $1.59M and leaving 262,900 shares worth $5.75M. The position accounts for 0.72% of the portfolio, ranked #38.

Atika Capital Management first reported a position in IMNM in Q1 2024 and has held it in 4 quarters since. The position peaked at $7.77M in Q1 2024. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Atika Capital Management held 262,900 shares of Immunome worth $5.75M as of Q1 2026.
  • Atika Capital Management sold 71,441 Immunome shares in Q1 2026, an estimated $1.59M.
  • Immunome made up 0.72% of Atika Capital Management's portfolio in Q1 2026, its #38 holding.
  • Atika Capital Management first reported a position in Immunome in Q1 2024 and has held it in 4 quarters since.
  • Atika Capital Management's Immunome position peaked at $7.77M in Q1 2024.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Atika Capital Management's 13F filing for Q1 2026, filed 14 May 2026.